First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study - Metges, J P; Kato, K; Sun, J M
2022 ASCO Gastrointestinal Cancers Symposium